[Expression of P53, P63, and C-erbB-2 in endometrioid adenocarcinoma and their clinicopathological significance].
OBJECTIVE
Tumor suppressor gene p53 and oncogene C-erbB-2 are confirmed to have close relation with endometrioid adenocarcinoma (EC), few documents have been reported about their correlation. Its structural homology to p53, p63 has been considered as a tumor suppressor gene acompany with p53 mutation, but its suppressive nature has not been confirmed yet; reports about p63 expression in EC are rare. This study was designed to investigate the roles of p53, p63, and C-erbB2 in tumorigenesis and development of EC, and their correlation with clinicopathological features of EC.


METHODS
Immunohistochemical technique was used to detect P53, P63, and C-erbB2 protein expression in 38 cases of EC, 23 cases of endometrial hyperplasia (EH), and 10 cases of benign proliferative endometrium (BPE).


RESULTS
(1) The positive rate of P53 in EC was 31.6%,significantly higher than those in EH and BPE (P < 0.05). P53 expression was associated with surgical pathologic stage, and depth of myometrial invasion in EC (P< 0.005), but was not associated with histological grade (P >0.05). (2) The positive rate of P63 in EC was 81.6%, significantly higher than those in EH and BPE (P < 0.005). P63 expression was not associated with histological grade, surgical pathologic stage, and depth of myometrial invasion in EC (P >0.05). (3) The positive rate of C-erbB-2 in EC was 23.2%, there was no significant difference compared with those in EH or BPE (P >0.05).C-erbB-2 expression was associated with surgical pathologic stage, and depth of myometrial invasion in EC (P< 0.001,P< 0.005),but was not associated with histological grade (P >0.05).(4) There was significantly positive correlation between P53 and P63 (r =0.443,P < 0.01)or C-erbB-2 (r =0.490,P < 0.005).


CONCLUSIONS
Both p53 and p63 are involved in carcinogenesis of EC; p63 may act as an oncogene in tumorigenesis of EC. The expression of P53 and C-erbB2 are related to the progression of malignant EC; P53 and C-erbB-2 co-expression may predict poor prognosis.
Hu
Wen-Fang
WF
Department of Obstetrics and Gynecology, Central Hospital of Huangshi City, Medical College, Wuhan University, Huangshi, Hubei, 435000, PR China.
Liu
Ming-Qiu
MQ
Zhao
Qing
Q
D000328:Adult; D000368:Aged; D018269:Carcinoma, Endometrioid / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D004268:DNA-Binding Proteins; D004714:Endometrial Hyperplasia / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D016889:Endometrial Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D005260:Female; D016147:Genes, Tumor Suppressor; D018734:Genes, erbB-2; D016158:Genes, p53; D006801:Humans; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D010750:Phosphoproteins / Q000378:metabolism*; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D015534:Trans-Activators / Q000378:metabolism*; D014157:Transcription Factors; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism*; D025521:Tumor Suppressor Proteins
D004268:DNA-Binding Proteins; D010750:Phosphoproteins; D018719:Erb-b2 Receptor Tyrosine Kinases; D015534:Trans-Activators; D014157:Transcription Factors; D016159:Tumor Suppressor Protein p53; D025521:Tumor Suppressor Proteins; C115051:TP63 protein, human